Beneficial effects of Etanercept on experimental necrotizing enterocolitis

Basit Öğe Kaydı
dc.authoridOncel, Mehmet Yekta/0000-0003-0760-0773
dc.authoridUysal, Bulent/0000-0003-1254-9749
dc.authoridERDEVE, OMER/0000-0002-3193-0812
dc.authoridCanpolat, Fuat Emre/0000-0001-9307-3003
dc.authorwosidERDEVE, Omer/W-1480-2017
dc.authorwosidOncel, Mehmet Yekta/L-5664-2013
dc.authorwosidCanpolat, Fuat Emre/P-3992-2018
dc.contributor.authorYurttutan, Sadik
dc.contributor.authorOzdemir, Ramazan
dc.contributor.authorCanpolat, Fuat Emre
dc.contributor.authorOncel, Mehmet Yekta
dc.contributor.authorUnverdi, Hatice Germen
dc.contributor.authorUysal, Bulent
dc.contributor.authorErdeve, Omer
dc.date.accessioned2024-08-04T20:38:01Z
dc.date.available2024-08-04T20:38:01Z
dc.date.issued2014
dc.departmentİnönü Üniversitesien_US
dc.description.abstractTissue damage in necrotizing enterocolitis (NEC) of infants occurs as a result of an uncontrolled inflammatory response. The aim of this study was to investigate any potential anti-inflammatory effects that Etanercept may have on the inflammatory response in an experimental NEC model in newborn rats. Newborn pups were randomized into three groups immediately after birth (Control, NEC + Placebo and NEC + Etanercept). Pups in the NEC + Placebo and NEC + Etanercept groups were subjected to an NEC-inducing protocol (hypercarbia, hypothermia and hyperoxia) twice a day for 3 days. Pups in the NEC + Etanercept group were given an intraperitoneal injection of Etanercept. Rats were harvested for biochemical and histopathological examinations. The histopathological injury score of rats in the NEC + Placebo group was significantly higher compared to the NEC + Etanercept and Control groups (p < 0.05 for both comparisons). Tissue levels of tumor necrosis factor-alpha, interleukin-1 beta, and malondialdehyde were higher in the placebo group compared to the Etanercept group. Our results suggest that Etanercept attenuates intestinal tissue damage in NEC by reducing inflammation and blocking the production of free-oxygen radicals, while also reducing tissue levels of tumor necrosis factor-alpha and interleukin-1 beta.en_US
dc.identifier.doi10.1007/s00383-013-3415-4
dc.identifier.endpage77en_US
dc.identifier.issn0179-0358
dc.identifier.issn1437-9813
dc.identifier.issue1en_US
dc.identifier.pmid24072202en_US
dc.identifier.scopus2-s2.0-84892606356en_US
dc.identifier.scopusqualityQ2en_US
dc.identifier.startpage71en_US
dc.identifier.urihttps://doi.org/10.1007/s00383-013-3415-4
dc.identifier.urihttps://hdl.handle.net/11616/96324
dc.identifier.volume30en_US
dc.identifier.wosWOS:000329237900010en_US
dc.identifier.wosqualityQ3en_US
dc.indekslendigikaynakWeb of Scienceen_US
dc.indekslendigikaynakScopusen_US
dc.indekslendigikaynakPubMeden_US
dc.language.isoenen_US
dc.publisherSpringeren_US
dc.relation.ispartofPediatric Surgery Internationalen_US
dc.relation.publicationcategoryMakale - Uluslararası Hakemli Dergi - Kurum Öğretim Elemanıen_US
dc.rightsinfo:eu-repo/semantics/closedAccessen_US
dc.subjectNecrotizing enterocolitisen_US
dc.subjectEtanercepten_US
dc.subjectTumor necrosis factor-alphaen_US
dc.titleBeneficial effects of Etanercept on experimental necrotizing enterocolitisen_US
dc.typeArticleen_US

Dosyalar

Koleksiyon

WoS İndeksli Yayınlar Koleksiyonu
PubMed İndeksli Yayın Koleksiyonu
Scopus İndeksli Yayınlar Koleksiyonu